Recognizing and Diagnosing the Subtleties of Carcinoid Syndrome
This case and the associated images have been provided by Rodney Pommier, MD (Professor of Surgery, Division of Surgical Oncology, Oregon Health & Science University, Portland, OR.)
Patient Background
- 54-year-old postmenopausal woman
- Married with 2 adult children
- History of hypertension
- Previously diagnosed with mild irritable bowel syndrome (IBS) with diarrhea
- – Family history is negative for both
Case History
- Presents to internist for care of hot flashes that have returned 2 years after menopause
- – Occur mostly after meals, when she drinks wine and when she goes running
- Referred to gynecologist
- – Physical examination is entirely normal
- – Experiences 2 hot flashes with no sweating during the examination
- Hormone-replacement therapy (HRT) is prescribed
- Referred to gastroenterologist for IBS treatment
3-Month Follow-up
- Patient has experienced no improvement of hot flashes
- A different formulation of HRT is prescribed
12-Month Follow-up
- Returns to gastroenterologist with worsening of her IBS like symptoms
- – Reports cramping
- – Abdominal pain
- – Increased episodes of diarrhea
- Wakes up at night with diarrhea
- Patient discontinued her HRT medication, feeling they were ineffective
- Patient is prescribed an antidiarrheal and antispasmodics, for control of diarrhea
21-Month Follow-up
Patient is in need of emergency care
- Patient presents with acute bowel obstruction and is taken to operating room
- – There is marked fibrosis of the terminal ileum with multiple hairpin turns of the bowel and a small tumor in the terminal ileum (Figure 1)
Figure 1. Small Bowel Obstruction
- Tumor is surgically resected (Figure 2)
Figure 2. Bowel Resection Surgical Specimen
- Surgical investigation revealed multiple metastatic tumors in lobes of the liver (Figure 3).
Figure 3. Liver Metastases
- Biopsies of the liver tumors were taken
Pathological Report
Small bowel and cecal resection reveals:
- Carcinoid tumor, 1.5 cm, with intense peritoneal sclerosis
- Metastatic carcinoid in 10 of 23 mesenteric lymph nodes
- Liver masses determined to be metastatic carcinoid tumors
Diagnostic Conclusion
- The patient had carcinoid syndrome
Oncologist Consulted
Postsurgical follow-up with an oncologist included:
- OctreoScanTM*
- 5-hydroxyindoleacetic acid (5-HIAA) and chromogranin A (CgA) level evaluation
- – Both levels were markedly elevated
- Patient was advised to maintain a record of symptom frequency and severity
- Follow-up appointment scheduled
* OctreoScan is a trademark of Covidien AG or one of its affiliates
Decipher the Evidence Early
Evidence
- The patient was experiencing nocturnal diarrhea
Conclusion
- IBS-associated diarrhea stops during sleep, so this patient may not be experiencing IBS
Evidence
- Hot flashes were not associated with sweating and did not improve with HRT
Conclusion
- Menopausal hot flashes and most other causes of flushing are associated with sweating, so the patient may not be experiencing menopausal hot flashes
- Carcinoid-associated flushing has no sympathetic component, and thus is "dry"
Evidence
- The patient's diarrhea was exacerbated by eating, drinking wine, and running
Conclusion
- Carcinoid syndrome is exacerbated by the 5 E's:
- – Eating
- – Epinephrine
- – Emotion
- – Ethanol
- – Exercise
- This patient may be experiencing carcinoid syndrome
Carcinoid Tumors—Diagnose early to help gain control over
debilitating symptoms
- Many patients with carcinoid tumors remain misdiagnosed for up to 5 to 7 years1–3
- The 5-year survival rate decreases based on the extent of metastatic disease4*
- – 78.2% survival rate with localized tumor
- – 71.7% survival rate with regional metastases
- – 38.5% survival rate with distant metastases
- Carcinoid syndrome can be commonly misdiagnosed as IBS or menopause
If Carcinoid Syndrome is Suspected:
- 5-HIAA and serum CgA level testing can help confirm the diagnosis
- OctreoScanTM is helpful for imaging and tumor staging
* These data are from The National Cancer Institute Surveillance, Epidemiology and End Results (SEER) 1992-1999 Registry.
